TSH Biopharm Corporation Limited reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 98.85 million compared to TWD 100.25 million a year ago. Revenue was TWD 98.85 million compared to TWD 100.25 million a year ago. Net income was TWD 9.89 million compared to TWD 15.51 million a year ago. Basic earnings per share from continuing operations was TWD 0.26 compared to TWD 0.4 a year ago. Diluted earnings per share from continuing operations was TWD 0.26 compared to TWD 0.4 a year ago. For the nine months, sales was TWD 305.89 million compared to TWD 322.99 million a year ago. Revenue was TWD 305.89 million compared to TWD 322.99 million a year ago. Net income was TWD 32.62 million compared to TWD 47.3 million a year ago. Basic earnings per share from continuing operations was TWD 0.85 compared to TWD 1.23 a year ago. Diluted earnings per share from continuing operations was TWD 0.85 compared to TWD 1.23 a year ago.